Atlantic Research Group

Our Mission

Everyone Deserves To Be Well

ARG is an oncology, immunology, rare and neurodegenerative disease-focused contract research organization that provides comprehensive clinical program development services ranging from pre-launch consulting to commercialization.

 

Founded in 2004 with the vision that every project should be highly individualized and visible, ARG has experienced consistent growth across the globe, expanding our reach to include drug and device strategic consulting, clinical trial management services, and clinical data and analytic solutions. ARG is a disrupter, using first-in-class technology platforms along with relationship-driven flexibility to optimize clinical studies because we believe everyone deserves to be well.

NORTHERA®       Chelsea Therapeutics

The Journey to Droxidopa

Chelsea Therapeutics was in the process of licensing droxidopa for treating neurogenic orthostatic hypotension, but the study suffered from low patient recruitment. ARG was brought in to improve enrollment.

LEARN MORE ›

CINRYZE®       Lev Pharmaceuticals

A Life-saving Drug's Race to America

Cinryze is used to treat hereditary angioedema, or HAE, a genetic defect that results in dysfunctional C1 esterase inhibitor. ARG helped Lev Pharmaceuticals conduct the trials and bring the drug to the market after a troubled history.

LEARN MORE ›

Jane’s Journey

Seeing the rare disease landscape from a mother’s perspective

Atlantic Research Group

In 2006, Jane discovered that her 15-month-old son had histiocytosis, an autoimmune disorder that is only diagnosed in approximately five out of every one million individuals. Suddenly, she and her family were forced to navigate the complex and unfamiliar terrain of what she dubbed “rare disease land.”

Stressed over the health of her loved one, Jane wanted to know everything about protecting her son in this new environment. Which treatment options were best? Would a clinical trial be beneficial? What was the total care concept? She was overwhelmed by a thousand questions, and the answers weren’t always straightforward. While complex clinical language was second nature to organizations that worked with rare diseases, Jane needed someone to translate and guide her family through the patient journey. Eventually, she found individuals who could.

Jane met doctors who didn’t define her son by his disease and served as advocates, seeking additional expertise when their own did not suffice. She connected with dedicated support networks that provided resources for understanding and navigating the clinical landscape. Although rare disease research was fraught with uncertainty—sometimes it seemed like 10% science and 90% art—these passionate people helped Jane’s family feel empowered rather than powerless. Today, she serves as a board member of the Histiocytosis Association, supporting others who seek guidance for their own journeys.

Atlantic Research Group
Community
fuels passion and progress
 

The clinic isn’t the only place where we make strides. ARG works with a variety of stakeholder organizations, advancing care alongside other dedicated individuals who advocate research.

 
VWD Connect
Global Genes
The Hemophilia Alliance
ATHN
Histiocytosis Association
Socra
Immune Deficiency Foundation
HAEA
NHF
American Cancer Society
MNDA
ENCALS
Interested in Working with ARG?

Submit your request for proposal below.